Dabur vs Baidyanath Chyawanprash

Why this comparison exists

Dabur and Baidyanath are India's two largest Chyawanprash brands by retail volume. Together they hold the dominant share of the category. They are not the same product — they are two different interpretations of a classical Ayurvedic formulation, with different ingredient ratios, different sugar contents, and different price points.

I bought both at a pharmacy near Clock Tower in Dehradun on April 11, 2026. I am reporting what is printed on the jar. Where a brand does not disclose something, I say so — that is information for you.

The headline numbers

The label-by-label table

A quick primer for readers comparing these for the first time

If you are new to Chyawanprash entirely and you opened this comparison hoping it would tell you which one to buy: stay with me, because the structure of this comparison will be more useful than a verdict.

Chyawanprash is the most widely-consumed Ayurvedic preparation in India. The classical formulation is Amla-based, includes 40+ supporting herbs, and is preserved with sugar, ghee, and honey. Modern interpretations vary in sweetener choices, herb proportions, and marketing claims, but the core structure is recognisable across all major brands.

Dabur and Baidyanath are India's two largest Chyawanprash brands. Dabur is the modernised wave-three brand with aggressive marketing and modernised packaging. Baidyanath is the heritage brand with longer classical Ayurveda lineage and more traditional positioning.

This comparison walks through both labels side-by-side so you can see exactly what each one tells you and what each one doesn't. If neither product matches what you're looking for, the related links at the bottom point to the broader Chyawanprash ingredient analysis and the Amla scorecard for the dominant ingredient.

How both brands actually approach Chyawanprash differently

This is the section I think most readers would find most useful, because the two products are genuinely different in approach despite being similar in core formulation.

Neither approach is "better." They serve different consumer preferences. A consumer who values modernised marketing and specific trial-supported claims may prefer Dabur. A consumer who values traditional Ayurvedic heritage and lower price may prefer Baidyanath. Both deliver structurally similar formulations.

What you cannot tell from either label

I want to be transparent about the limits of this label-level analysis.

Neither label tells you the precise milligram quantity of each individual herb. Both lists ingredients in roughly descending order of weight, but exact percentages are not disclosed. The classical formulation has documented proportions, but commercial reformulations may vary.

Neither label tells you the geographical sourcing of the Amla or the supporting herbs. Indian-grown vs imported, organic vs conventional, freshly-harvested vs stored — all of these affect the actual product but none of these is disclosed on the outer label.

Neither label tells you the specific preservation method (heat treatment, cold processing, traditional concentration) used. These choices affect the bioactive compound retention in the final product.

Neither label provides a heavy-metal Certificate of Analysis. Heavy-metal contamination in mass-produced Indian Ayurvedic supplements has been documented in some independent testing; whether either Dabur or Baidyanath products have been independently tested at batch level is not disclosed on the packaging.

These are not criticisms specific to Dabur or Baidyanath — most Indian Ayurvedic supplement labels share these gaps. But they limit what consumers can verify, and they explain why I keep coming back to disclosure quality as a meaningful differentiator across the category.

What each brand actually claims on its packaging

Direct quotes, attributed.

The "3X immunity" claim on Dabur's label references the multi-centre paediatric trial published in the Journal of Ayurveda and Integrative Medicine (Sharma et al., 2017). The Baidyanath claim is more general — framed as traditional rasayana use without a specific quantified marketing number.

Both framings are within the bounds of what Indian regulation allows for this product category. The Dabur framing is more aggressive in marketing language; the Baidyanath framing is more traditional.

Key formulation differences

Both products are built around Amla (Indian gooseberry) as the primary herb, with a similar 40+ herb supporting cast that includes the classical Chyawanprash components. The differences are in proportions and detail:

Both use Amla, sugar, ghee, honey, sesame oil, and the standard supporting herb cast. The taste profiles are noticeably different — Dabur tends toward sweeter, Baidyanath toward more bitter-pungent.

Sugar content side-by-side

This is the section many readers will care about most.

Both regular versions deliver roughly 35-40% of the WHO daily added-sugar limit per single serving. Two daily servings of either delivers 70-80% of that limit. The Sugar Free version (Dabur is the most widely available) is sweetened with sucralose and contributes negligible sugar.

What the published evidence actually shows

The clinical trial base for Chyawanprash specifically (as distinct from individual ingredient research) is small.

The most-cited trial is Sharma et al., 2017 (multi-centre paediatric study in 5-12 year olds), which reported improvements in self-reported immunity-related parameters and quality of life over 6 months. The trial was funded with Dabur involvement and tested the Dabur formulation specifically.

A COVID-era trial in healthcare workers (Devpura et al., 2021) reported reduced infection rates with Chyawanprash supplementation in an open-label multi-centre study at five Indian sites.

No published RCT directly compares Dabur vs Baidyanath Chyawanprash head-to-head. Both brands rely on the broader Chyawanprash literature plus claims about their own formulations.

Value math

Baidyanath is roughly 22% cheaper per gram. Whether that price differential is meaningful depends on your daily-use pattern — a person taking 2 teaspoons daily saves about Rs 36/month with Baidyanath vs Dabur.

Questions to ask yourself before buying either

How brand familiarity is shaping consumer choice in this category

Most Indian consumers buying Chyawanprash choose between Dabur and Baidyanath based on parent or family preference rather than label-level analysis. Both brands have decades of household familiarity. Both maintain comparable quality-control infrastructure for this product category.

The case for Dabur over Baidyanath: more aggressive marketing, slightly more accessible packaging, the Sugar Free variant is more widely distributed, and a published clinical trial specifically of their formulation.

The case for Baidyanath over Dabur: lower price, more traditional positioning, less marketing-language inflation around immunity claims, and longer brand heritage in classical Ayurveda specifically.

Neither case is decisive. Most consumers can defensibly choose either based on personal preference.

What other Chyawanprash brands offer that these two don't

For readers considering brands beyond Dabur and Baidyanath, three meaningful alternatives exist in the Indian market.

Each brand serves a different consumer segment. The Dabur vs Baidyanath comparison is the most-searched because they dominate market share, but Indian consumers have meaningful alternatives if neither suits their priorities.

What classical Ayurveda actually said about which Chyawanprash is "better"

The classical text Charaka Samhita describes Chyawanprash as a rasayana originally formulated by the Ashwin twins for the elderly sage Chyawan. The text specifies the core formulation but doesn't compare different "brands" — that's a modern commercial concept.

What Ayurvedic practitioners traditionally weighted: freshness of ingredients (especially fresh Amla), proper preparation methods (lengthy concentration over fire, careful sequence of additions), correct proportions of the supporting herbs, and the practitioner's own expertise.

These traditional quality criteria don't map cleanly to modern commercial quality criteria (FSSAI registration, GMP certification, batch consistency). Both Dabur and Baidyanath operate at industrial scale that classical practitioners would not have recognised, and both produce a more standardised but potentially less individualised product than traditional preparation.

This isn't a criticism of either modern brand. It's an acknowledgment that "best Chyawanprash" in the classical sense and "best Chyawanprash" in the modern commercial sense are different questions with different answers.

What I would actually choose — three reader scenarios

Let me make this practically useful with three concrete scenarios.

These are not medical recommendations. They are scenario-based purchase reasoning that should help you map your priorities to the available products.

What I changed my mind about while writing this comparison

I came into this comparison expecting Dabur to win on most evidence-quality dimensions, given their stronger marketing and clinical trial investment. The actual side-by-side analysis was more nuanced.

On evidence specifically — yes, Dabur has the published trial advantage. The 2017 paediatric multi-centre study and the 2021 COVID-era healthcare worker study both used the Dabur formulation. Baidyanath does not have equivalent specific-formulation published trials.

On formulation and ingredient quality — the two are structurally similar. Both use the standard 40+ herb classical formulation. Both maintain reasonable quality control infrastructure. Both have FSSAI registration. Differences in specific herb ratios may exist but neither label discloses them precisely enough to compare.

On price-to-value — Baidyanath wins clearly. 22% lower per gram with structurally similar formulation is meaningful for a daily-use product over months and years.

On marketing transparency — Dabur is more aggressive in its specific quantified claims ("3X immunity"); Baidyanath is more traditional in its general framing. Whether you prefer specific-but-marketing-extended claims or general-but-traditional positioning is a matter of consumer preference, not objective superiority.

The honest synthesis: Dabur has the evidence pedigree premium. Baidyanath has the price-value advantage. Both deliver structurally similar Chyawanprash. Most Indian consumers can defensibly choose either based on personal priorities.

What's worth tracking in this category

Three trends I would watch over the next 12 months in the Indian Chyawanprash category.

The continuing growth of Sugar Free variants. Both Dabur and Baidyanath now offer Sugar Free options; expect this segment to grow as Indian consumer awareness of metabolic-health concerns expands. The trade-off conversation between sugar and non-nutritive sweeteners will continue evolving.

Possible RCTs of the Baidyanath formulation specifically. Baidyanath has the brand heritage to support funding such research; whether they will commercially invest in matching Dabur's trial pedigree remains to be seen.

Premium positioning entrants. Wave-three brands have largely not entered Chyawanprash yet at meaningful scale. If a premium-positioned modernised Chyawanprash brand launches with strong disclosure transparency and trial evidence, it could meaningfully shift the category dynamics that currently have Dabur and Baidyanath as the dominant duopoly.

I revisit this comparison every six months. The Indian Chyawanprash market is more dynamic than its centuries-old product heritage suggests.

What this comparison teaches about Indian heritage Ayurveda brands generally

The Dabur vs Baidyanath comparison is useful beyond just Chyawanprash because it reflects a broader pattern in Indian heritage Ayurveda brand competition.

Heritage brands compete on familiarity, distribution, and price more than on disclosure transparency or specific clinical evidence. Both Dabur and Baidyanath are well over 100 years old. Neither needs to differentiate aggressively on label specifications because their core consumer base trusts the brand from generations of household use.

This pattern explains why wave-three brands (Carbamide Forte, Kapiva, etc.) have entered the broader Indian Ayurveda market — they bring the disclosure transparency and modernised marketing that heritage brands haven't needed to develop. Whether they will displace heritage brands at scale remains to be seen.

For consumers, the practical implication: heritage brands like Dabur and Baidyanath deliver structurally reasonable products with strong baseline quality control, but limited specification transparency. If specification transparency matters to you, the wave-three alternative is worth considering. If brand familiarity and price-value matter more, heritage brands deliver well.

This applies to Chyawanprash specifically and to Indian Ayurveda commerce generally. The category is in a transition where multiple business models coexist, each serving different consumer priorities.

Frequently asked questions

Related reads on HerbVerdict